ALS Ltd shares (ASX: ALQ) are down 2.12% at A$21.73 today, despite the company reporting record FY26 results. What is causing the disconnect?
The ALS share price sits at A$21.73, down from A$22.20 on the day, having swung positive with an intraday high at A$22.90, only to again pull back in the afternoon session. The negative reaction stands in contrast to the headline numbers, suggesting markets had already priced in a strong result and are now focusing on valuation multiples and execution risks rather than backward-looking beats.
Record Financial Performance
ALS reported revenue of A$3.32 billion for FY26, representing growth of 10.7% year-on-year, driven by strong organic expansion across its core divisions. Underlying net profit after tax surged 25.8% to A$381.2 million, while statutory NPAT rose 24.4% to A$318.7 million. The company’s underlying EBIT climbed 19.3% to A$599.0 million, with the EBIT margin expanding 129 basis points to 18.0%, demonstrating improved operational leverage.
Free cash flow generation remained robust at A$674.1 million, with EBITDA-to-cash conversion reaching 92%, underscoring the quality of earnings and the company’s ability to translate profits into cash. The board declared a final dividend of 23.1 cents per share (partially franked), bringing the full-year distribution to 42.5 cents, an increase of approximately 10% on FY25’s 38.6 cents per share and representing a payout ratio of around 57% of underlying earnings.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The Commodities division delivered the standout performance, with revenue jumping 18.8% on the back of increased mineral exploration activity globally. Management attributed the growth to both market-share gains and a strengthening exploration cycle as mining companies ramp up spending to replenish reserves. The Industrial Materials segment also contributed solid growth, positioning the combined Minerals and Industrial Materials divisions for continued double-digit and high single-digit expansion respectively in FY27.
Life Sciences grew revenue by 6%, with the Food testing business performing particularly well. However, the Environmental segment within Life Sciences faced headwinds in the Americas, with softer market conditions compounded by internal operational challenges. Management indicated these issues are being actively addressed through restructuring and process improvements.
ALS strengthened its balance sheet materially during the year, reducing financial leverage to 1.5 times net debt-to-EBITDA, below the company’s target range, through a combination of strong cash generation and the successful equity raising completed in FY25. The company deployed capital into four new hub laboratories across its Minerals and Environmental networks, investments designed to increase capacity and improve turnaround times in high-demand markets.
Two major facilities, a Life Sciences and Environmental laboratory in Sydney and a Minerals laboratory in Peru are scheduled for commissioning in the second half of FY27, adding further capacity in strategically important geographies.
Outlook and Guidance
Looking ahead to FY27, management guided for mid-to-high single-digit organic revenue growth at the group level, with further margin expansion expected as operational efficiencies from recent investments flow through. The Minerals division is forecast to deliver double-digit growth, Industrial Materials high single-digit growth, and Life Sciences improved mid-single-digit organic expansion as Environmental challenges are resolved.
Management acknowledged macro uncertainties, including global growth dynamics, supply chain risks, and the sustainability of the current exploration cycle. However, the company’s strengthened balance sheet provides flexibility to pursue both organic growth initiatives and bolt-on acquisitions should attractive opportunities arise.
Valuation Concerns Weigh on Sentiment
Despite the strong operational performance, the stock trades on a forward price-to-earnings multiple of more than 39 times, a premium valuation that reflects high expectations for sustained growth and margin improvement.
The post-earnings dip suggests markets are applying a higher discount rate to future earnings, factoring in cyclical exposure to commodities, execution risk on major capital projects, and the potential for valuation compression if growth moderates. With single digit growth guided in two of the three divisions, markets may need to see more in order to deserve such a premium.
Bull Case:
- Record earnings with 25.8% NPAT growth and expanding margins demonstrate operational excellence
- Double-digit Minerals growth leverages strengthening global exploration cycle and market-share gains
- Leverage at 1.5x provides significant balance sheet capacity for acquisitions and capital returns
- Lab of the Future automation and AI initiatives support multi-year structural margin expansion
- Strong 92% cash conversion and rising dividends underpin shareholder returns and earnings quality
Bear Case:
- Valuation at 38–39x forward earnings leaves little room for disappointment or growth moderation
- Environmental segment weakness in Americas highlights execution risk and uneven divisional performance
- Cyclical exposure to commodities creates downside risk if exploration spending or mining activity softens
- Recent cyber security incident raises operational and compliance risks in digital laboratory environment
- Post-earnings selloff reflects stretched expectations and profit-taking after 25% twelve-month rally
